CD274 and ovarian carcinoma: We then evaluated the levels of PD‐L1 in DIRAS3‐knockdown SKOV3 cells and found that there was an approximate 40% increase in PD‐L1 levels in SKOV3‐siDIRAS3 cells compared with NC‐treated cells (Figure 4I), indicating that DIRAS3‐knockdown SKOV3 cells are more immunoreactive and may be more sensitive to an anti‐PD‐L1 approach; such verification reinforced our prediction that the activated‐immune subtype of ovarian cancer was more sensitive to immunotherapy.